Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Rigenera HBW is an Italian regenerative medicine and medical device company that develops and manufactures the patented Rigenera autologous micrografting technology. Its platform uses disposable and electromechanical devices to mechanically disaggregate a patient's own tissue into micrograft suspensions for minimally invasive regenerative procedures. The company commercializes products and protocols across wound healing, dental and oral-maxillofacial surgery, dermatology, aesthetic medicine, orthopedics, pain management, and sports medicine. Rigenera HBW operates from its Piedmont technology hub and has expanded internationally through offices and distribution activities in multiple regions. The business appears focused on commercial-stage medical devices and protocol development rather than a traditional drug pipeline.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Rigenera HBW.